Antineoplaston Therapy in Treating Patients With Multiple Myeloma
Status:
Terminated
Trial end date:
1999-10-21
Target enrollment:
Participant gender:
Summary
Current therapies for Multiple Myeloma provide limited benefit to the patient. The
anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the
treatment of Multiple Myeloma.
PURPOSE: This study is being performed to determine the effects (good and bad) that
Antineoplaston therapy has on patients with Multiple Myeloma.